Theratechnologies, Inc. (THTX) News

Theratechnologies, Inc. (THTX): $0.98

0.02 (+2.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add THTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 381

in industry

Filter THTX News Items

THTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest THTX News From Around the Web

Below are the latest news stories about THERATECHNOLOGIES INC that investors may wish to consider to help them evaluate THTX as an investment opportunity.

Open Letter to Shareholders from CEO Paul Levesque

Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key ObjectivesFY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidanceFY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash flow from operating activitiesFY2023 operating plan to focus on achieving positive EBITDA1 in the near-term based on commercial business growth and new asset opportunities

Yahoo | January 4, 2023

Shareholders in Theratechnologies (TSE:TH) are in the red if they invested five years ago

Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held...

Yahoo | December 23, 2022

Theratechnologies Announces Update from Ongoing TH1902 Study

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021.MONTREAL, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of p

Yahoo | December 1, 2022

Theratechnologies Is An Underappreciated HIV-Focused Company, Analyst Says

Cantor Fitzgerald has initiated coverage on Theratechnologies Inc (NASDAQ: THTX) with an Overweight rating and a price target of $9. Theratechnologies' two HIV drugs, Egrifta and Trogarzo, could grow 20% a year for the foreseeable future, the analyst writes. Being conservative, Cantor has modeled a mid-teens sales growth for these two products. Product innovations and dedicated sales focus on these two drugs have driven uptake. THTX's decision to internalize its field force and strengthen its co

Yahoo | November 17, 2022

Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays

Poster for presentation at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics enhances understanding of SORT1 expression in healthy and tumor tissuesExtensive dataset underscores potential of SORT1 as a new anticancer therapeutic target MONTREAL, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies re

Yahoo | October 26, 2022

10 Best Low Price Pharma Stocks To Buy Now

In this article, we discuss 10 best low price pharma stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Low Price Pharma Stocks To Buy Now. The global pharmaceuticals market was forecasted to grow from $1454.66 billion in 2021 to $1587.05 billion in 2022 at a […]

Yahoo | October 18, 2022

Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update

- Q3 2022 Consolidated Revenue Growth of 17% to $20.8 million - Q3 2022 North American Revenue Growth of 19% - TH1902 Phase 1 basket trial proceeding as planned - On track to meet FY2022 Revenue Guidance $79 - $82 million MONTREAL, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and finan

Yahoo | October 13, 2022

Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium

MONTREAL, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of SORT1, the target for Theratechnologies’ oncology platform, in several cancer types. The data will be presented in a poster session at the 34th joint symposium of t

Yahoo | October 12, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, investor!

William White on InvestorPlace | October 4, 2022

Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population

Reduces maintenance dose from a 15-minute IV infusion to a 30-second, undiluted IV push every two weeksSafety profile of Trogarzo® IV push similar to that of IV infusionNew method of administration designed to make maintenance dosing easier for patients and health care providers and allow more clinics to administer treatment MONTREAL, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on th

Yahoo | October 3, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5434 seconds.